Biohaven announces fda acceptance and priority review of troriluzole new drug application for the treatment of spinocerebellar ataxia

Spinocerebellar ataxia (sca) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. troriluzole demonstrated a 50-70% slowing of sca disease progression on the primary and secondary outcome measures at the 3-year endpoint in a real-world evidence (rwe) study.
BHVN Ratings Summary
BHVN Quant Ranking